期刊
JOURNAL OF LIPID RESEARCH
卷 53, 期 2, 页码 282-291出版社
ELSEVIER
DOI: 10.1194/jlr.M021261
关键词
Gaucher disease; blood-brain barrier; glycosphingolipid; synthesis inhibition therapy; eliglustat tartrate
资金
- National Institutes of Health [5R21NS065492-02, 5RO1DK055823-11]
- Michigan Institute for Clinical and Health Research
- National Tay-Sachs and Allied Disease Foundation
Synthesis inhibition is the basis for the treatment of type 1 Gaucher disease by the glucosylceramide synthase (GCS) inhibitor eliglustat tartrate. However, the extended use of eliglustat and related compounds for the treatment of glycosphingolipid storage diseases with CNS manifestations is limited by the lack of brain penetration of this drug. Property modeling around the D-threo-1-phenyl-2-decanoylamino3- morpholino-propanol (PDMP) pharmacophore was employed in a search for compounds of comparable activity against the GCS but lacking P-glycoprotein (MDR1) recognition. Modifications of the carboxamide N-acyl group were made to lower total polar surface area and rotatable bond number. Compounds were screened for inhibition of GCS in crude enzyme and whole cell assays and for MDR1 substrate recognition. One analog, 2-(2,3-dihydro-1H-inden-2-yl)-N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy3-(pyrrolidin-1-yl)propan-2-yl)acetamide (CCG-203586), was identified that inhibited GCS at low nanomolar concentrations with little to no apparent recognition by MDR1. Intraperitoneal administration of this compound to mice for 3 days resulted in a significant dose dependent decrease in brain glucosylceramide content, an effect not seen in mice dosed in parallel with eliglustat tartrate.-Larsen, S.D., M.W. Wilson, A. Abe, L. Shu, C.H. George, P. Kirchhoff, H.D.H. Showalter, J. Xiang, R.F. Keep, and J.A. Shayman. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J. Lipid Res. 2012. 53: 282-291.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据